Cargando…

Impact of lymph node ratio on survival in stage IIIC endometrioid endometrial cancer: a Turkish Gynecologic Oncology Group study

OBJECTIVE: The purpose of this study was to investigate the prognostic value of lymph node ratio (LNR) in women with stage IIIC endometrioid endometrial cancer (EC). METHODS: A multicenter, retrospective department database review was performed to identify patients with stage IIIC pure endometrioid...

Descripción completa

Detalles Bibliográficos
Autores principales: Ayhan, Ali, Topfedaisi Ozkan, Nazlı, Öz, Murat, Kimyon Comert, Günsu, Firat Cuylan, Zeliha, Çoban, Gonca, Turkmen, Osman, Erdem, Baki, Şahin, Hanifi, Akbayır, Özgür, Dede, Murat, Turan, Ahmet Taner, Celik, Husnu, Güngör, Tayfun, Haberal, Ali, Arvas, Macit, Meydanli, Mehmet Mutlu
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Asian Society of Gynecologic Oncology; Korean Society of Gynecologic Oncology 2018
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5981100/
https://www.ncbi.nlm.nih.gov/pubmed/29770619
http://dx.doi.org/10.3802/jgo.2018.29.e48
_version_ 1783327974268862464
author Ayhan, Ali
Topfedaisi Ozkan, Nazlı
Öz, Murat
Kimyon Comert, Günsu
Firat Cuylan, Zeliha
Çoban, Gonca
Turkmen, Osman
Erdem, Baki
Şahin, Hanifi
Akbayır, Özgür
Dede, Murat
Turan, Ahmet Taner
Celik, Husnu
Güngör, Tayfun
Haberal, Ali
Arvas, Macit
Meydanli, Mehmet Mutlu
author_facet Ayhan, Ali
Topfedaisi Ozkan, Nazlı
Öz, Murat
Kimyon Comert, Günsu
Firat Cuylan, Zeliha
Çoban, Gonca
Turkmen, Osman
Erdem, Baki
Şahin, Hanifi
Akbayır, Özgür
Dede, Murat
Turan, Ahmet Taner
Celik, Husnu
Güngör, Tayfun
Haberal, Ali
Arvas, Macit
Meydanli, Mehmet Mutlu
author_sort Ayhan, Ali
collection PubMed
description OBJECTIVE: The purpose of this study was to investigate the prognostic value of lymph node ratio (LNR) in women with stage IIIC endometrioid endometrial cancer (EC). METHODS: A multicenter, retrospective department database review was performed to identify patients with stage IIIC pure endometrioid EC at 6 gynecologic oncology centers in Turkey. A total of 207 women were included. LNR, defined as the percentage of positive lymph nodes (LNs) to total nodes recovered, was stratified into 2 groups: LNR1 (≤0.15), and LNR2 (>0.15). Kaplan-Meier method was used to generate survival data. Factors predictive of outcome were analyzed using Cox proportional hazards models. RESULTS: One hundred and one (48.8%) were classified as stage IIIC1 and 106 (51.2%) as stage IIIC2. The median age at diagnosis was 58 (range, 30–82) and the median duration of follow-up was 40 months (range, 1–228 months). There were 167 (80.7%) women with LNR ≤0.15, and 40 (19.3%) women with LNR >0.15. The 5-year progression-free survival (PFS) rates for LNR ≤0.15 and LNR >0.15 were 76.1%, and 58.5%, respectively (p=0.045). An increased LNR was associated with a decrease in 5-year overall survival (OS) from 87.0% for LNR ≤0.15 to 62.3% for LNR >0.15 (p=0.005). LNR >0.15 was found to be an independent prognostic factor for both PFS (hazard ratio [HR]=2.05; 95% confidence interval [CI]=1.07–3.93; p=0.03) and OS (HR=3.35; 95% CI=1.57–7.19; p=0.002). CONCLUSION: LNR seems to be an independent prognostic factor for decreased PFS and OS in stage IIIC pure endometrioid EC.
format Online
Article
Text
id pubmed-5981100
institution National Center for Biotechnology Information
language English
publishDate 2018
publisher Asian Society of Gynecologic Oncology; Korean Society of Gynecologic Oncology
record_format MEDLINE/PubMed
spelling pubmed-59811002018-07-01 Impact of lymph node ratio on survival in stage IIIC endometrioid endometrial cancer: a Turkish Gynecologic Oncology Group study Ayhan, Ali Topfedaisi Ozkan, Nazlı Öz, Murat Kimyon Comert, Günsu Firat Cuylan, Zeliha Çoban, Gonca Turkmen, Osman Erdem, Baki Şahin, Hanifi Akbayır, Özgür Dede, Murat Turan, Ahmet Taner Celik, Husnu Güngör, Tayfun Haberal, Ali Arvas, Macit Meydanli, Mehmet Mutlu J Gynecol Oncol Original Article OBJECTIVE: The purpose of this study was to investigate the prognostic value of lymph node ratio (LNR) in women with stage IIIC endometrioid endometrial cancer (EC). METHODS: A multicenter, retrospective department database review was performed to identify patients with stage IIIC pure endometrioid EC at 6 gynecologic oncology centers in Turkey. A total of 207 women were included. LNR, defined as the percentage of positive lymph nodes (LNs) to total nodes recovered, was stratified into 2 groups: LNR1 (≤0.15), and LNR2 (>0.15). Kaplan-Meier method was used to generate survival data. Factors predictive of outcome were analyzed using Cox proportional hazards models. RESULTS: One hundred and one (48.8%) were classified as stage IIIC1 and 106 (51.2%) as stage IIIC2. The median age at diagnosis was 58 (range, 30–82) and the median duration of follow-up was 40 months (range, 1–228 months). There were 167 (80.7%) women with LNR ≤0.15, and 40 (19.3%) women with LNR >0.15. The 5-year progression-free survival (PFS) rates for LNR ≤0.15 and LNR >0.15 were 76.1%, and 58.5%, respectively (p=0.045). An increased LNR was associated with a decrease in 5-year overall survival (OS) from 87.0% for LNR ≤0.15 to 62.3% for LNR >0.15 (p=0.005). LNR >0.15 was found to be an independent prognostic factor for both PFS (hazard ratio [HR]=2.05; 95% confidence interval [CI]=1.07–3.93; p=0.03) and OS (HR=3.35; 95% CI=1.57–7.19; p=0.002). CONCLUSION: LNR seems to be an independent prognostic factor for decreased PFS and OS in stage IIIC pure endometrioid EC. Asian Society of Gynecologic Oncology; Korean Society of Gynecologic Oncology 2018-07 2018-03-13 /pmc/articles/PMC5981100/ /pubmed/29770619 http://dx.doi.org/10.3802/jgo.2018.29.e48 Text en Copyright © 2018. Asian Society of Gynecologic Oncology, Korean Society of Gynecologic Oncology https://creativecommons.org/licenses/by-nc/4.0/ This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (https://creativecommons.org/licenses/by-nc/4.0/) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Original Article
Ayhan, Ali
Topfedaisi Ozkan, Nazlı
Öz, Murat
Kimyon Comert, Günsu
Firat Cuylan, Zeliha
Çoban, Gonca
Turkmen, Osman
Erdem, Baki
Şahin, Hanifi
Akbayır, Özgür
Dede, Murat
Turan, Ahmet Taner
Celik, Husnu
Güngör, Tayfun
Haberal, Ali
Arvas, Macit
Meydanli, Mehmet Mutlu
Impact of lymph node ratio on survival in stage IIIC endometrioid endometrial cancer: a Turkish Gynecologic Oncology Group study
title Impact of lymph node ratio on survival in stage IIIC endometrioid endometrial cancer: a Turkish Gynecologic Oncology Group study
title_full Impact of lymph node ratio on survival in stage IIIC endometrioid endometrial cancer: a Turkish Gynecologic Oncology Group study
title_fullStr Impact of lymph node ratio on survival in stage IIIC endometrioid endometrial cancer: a Turkish Gynecologic Oncology Group study
title_full_unstemmed Impact of lymph node ratio on survival in stage IIIC endometrioid endometrial cancer: a Turkish Gynecologic Oncology Group study
title_short Impact of lymph node ratio on survival in stage IIIC endometrioid endometrial cancer: a Turkish Gynecologic Oncology Group study
title_sort impact of lymph node ratio on survival in stage iiic endometrioid endometrial cancer: a turkish gynecologic oncology group study
topic Original Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5981100/
https://www.ncbi.nlm.nih.gov/pubmed/29770619
http://dx.doi.org/10.3802/jgo.2018.29.e48
work_keys_str_mv AT ayhanali impactoflymphnoderatioonsurvivalinstageiiicendometrioidendometrialcanceraturkishgynecologiconcologygroupstudy
AT topfedaisiozkannazlı impactoflymphnoderatioonsurvivalinstageiiicendometrioidendometrialcanceraturkishgynecologiconcologygroupstudy
AT ozmurat impactoflymphnoderatioonsurvivalinstageiiicendometrioidendometrialcanceraturkishgynecologiconcologygroupstudy
AT kimyoncomertgunsu impactoflymphnoderatioonsurvivalinstageiiicendometrioidendometrialcanceraturkishgynecologiconcologygroupstudy
AT firatcuylanzeliha impactoflymphnoderatioonsurvivalinstageiiicendometrioidendometrialcanceraturkishgynecologiconcologygroupstudy
AT cobangonca impactoflymphnoderatioonsurvivalinstageiiicendometrioidendometrialcanceraturkishgynecologiconcologygroupstudy
AT turkmenosman impactoflymphnoderatioonsurvivalinstageiiicendometrioidendometrialcanceraturkishgynecologiconcologygroupstudy
AT erdembaki impactoflymphnoderatioonsurvivalinstageiiicendometrioidendometrialcanceraturkishgynecologiconcologygroupstudy
AT sahinhanifi impactoflymphnoderatioonsurvivalinstageiiicendometrioidendometrialcanceraturkishgynecologiconcologygroupstudy
AT akbayırozgur impactoflymphnoderatioonsurvivalinstageiiicendometrioidendometrialcanceraturkishgynecologiconcologygroupstudy
AT dedemurat impactoflymphnoderatioonsurvivalinstageiiicendometrioidendometrialcanceraturkishgynecologiconcologygroupstudy
AT turanahmettaner impactoflymphnoderatioonsurvivalinstageiiicendometrioidendometrialcanceraturkishgynecologiconcologygroupstudy
AT celikhusnu impactoflymphnoderatioonsurvivalinstageiiicendometrioidendometrialcanceraturkishgynecologiconcologygroupstudy
AT gungortayfun impactoflymphnoderatioonsurvivalinstageiiicendometrioidendometrialcanceraturkishgynecologiconcologygroupstudy
AT haberalali impactoflymphnoderatioonsurvivalinstageiiicendometrioidendometrialcanceraturkishgynecologiconcologygroupstudy
AT arvasmacit impactoflymphnoderatioonsurvivalinstageiiicendometrioidendometrialcanceraturkishgynecologiconcologygroupstudy
AT meydanlimehmetmutlu impactoflymphnoderatioonsurvivalinstageiiicendometrioidendometrialcanceraturkishgynecologiconcologygroupstudy